Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation

Lung Cancer. 2011 Jan;71(1):109-12. doi: 10.1016/j.lungcan.2010.09.011.

Abstract

Advanced thymic carcinoma (TC) is a very aggressive disease. To date there are no established treatment options for the refractory and recurrent disease and only a few prospective trials have been conducted in patients with TC. Here we present a case of a relapsed TC patient, who, by using combination chemotherapy, showed a positive response to sorafenib with C-KIT exon 11 mutation.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Benzenesulfonates / therapeutic use*
  • Exons
  • Female
  • Humans
  • Middle Aged
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Proto-Oncogene Proteins c-kit / genetics*
  • Pyridines / therapeutic use*
  • Sequence Deletion*
  • Sorafenib
  • Thymus Neoplasms / drug therapy*
  • Thymus Neoplasms / enzymology
  • Thymus Neoplasms / genetics*

Substances

  • Antineoplastic Agents
  • Benzenesulfonates
  • Phenylurea Compounds
  • Pyridines
  • Niacinamide
  • Sorafenib
  • Proto-Oncogene Proteins c-kit